Robert Farrell, J.D., President and CEO
Mr. Farrell has more than 25 years of experience in the pharmaceutical, biotechnology, and medical device sectors. Prior to joining Kalytera, Mr. Farrell worked as an executive officer with the Institute for OneWorld Health, an affiliate of the Bill and Melinda Gates Foundation. Mr. Farrell has held senior positions with publicly listed companies in the pharmaceutical and biotechnology industries, including Titan Pharmaceuticals, where he served as President and CEO from 2008 to 2009, and as Chief Financial Officer from 1996 to 2008. Mr. Farrell raised over $390M while at Titan via public equity and non-dilutive financings, including seven corporate partnerships. Prior to working with Titan, Mr. Farrell served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care, where he completed six corporate partnerships and M&A transactions totaling over $4B. Mr. Farrell received a law degree (J.D.) from the University of California, and his undergraduate degree (B.A.) from the University of Notre Dame.
Sari Prutchi-Sagiv, Ph.D., Chief Scientific Officer
Dr. Prutchi-Sagiv has over 15 years of experience in various aspects of pharmaceutical development including discovery, regulatory affairs, intellectual property, business development, clinical trials, and marketing. Dr. Prutchi-Sagiv has lead scientific operations in multiple cannabis-based drug companies including Talent Biotechs and BOL Pharma. She serves as Director of Tech Transfer at Mor Research Applications (Clalit Health Services commercializing arm), where she is responsible for raising capital via strategic partnerships for early stage technologies. Dr. Prutchi-Sagiv holds an M.Sc. in Human Genetics and a Ph.D. in Cell Biology and Immunology from Tel Aviv University. In addition, she studied Business Administration at the Recanati School of Business at Tel Aviv University.
Moshe Yeshurun, M.D., Chief Medical Officer
Dr. Yeshurun is Head of the Bone Marrow Transplantation Unit at the Rabin Medical Center in Petah-Tikva Israel. Dr. Yeshurun’s primary field of interest and research is GvHD following allogeneic hematopoietic cell transplantation (“HCT”). Dr. Yeshurun has conducted several innovative clinical studies aiming to explore the role of CBD in the prevention and treatment of GvHD. Dr. Yeshurun received his M.D. degree from Tel Aviv University Sackler School of Medicine with distinction in 1990 and his board certification in Internal Medicine and Hematology in 1996 and 2002, respectively. Dr. Yeshurun completed a fellowship in bone marrow transplantation at Saint-Antoine and Saint-Louis hospitals in Paris, France. In 2007, he established the Bone Marrow Transplantation Unit at the Davidoff Cancer Center, Rabin Medical Center and has headed it since. Between the 2014 and 2017, Dr. Yeshurun was a committee member of the Israeli Society of Hematology and Transfusion Medicine.
Victoria Rudman, Interim Chief Financial Officer, Treasurer and Secretary
Ms. Rudman brings over 20 years of financial leadership in the financial services and life sciences sectors to Kalytera. She served as Chief Financial Officer of Kalytera from March 2015 through June 2016 and continued to serve as Treasurer and Secretary of Kalytera since March 2015. Ms. Rudman previously held various positions in Morgan Stanley and Bear Stearns and a number of small cap public companies and startup ventures.
Ronen Raviv, Director of Finance
Mr. Raviv obtained his Bachelor degree in Business with concentration in accounting in 2006 from San Francisco State University. Upon graduating, he joined the EY San Francisco Office, where he carried out audits of private and public companies in the Silicon Valley, among them Oracle Corporation (Ticker: ORCL) and salesforce.com (Ticker: SFDC). In 2008 Mr. Raviv relocated to the Tel Aviv office of EY, where he worked primarily with clients in the technology and defense industries. Mr. Raviv’s main client at EY was Elbit Systems Ltd. (Ticker: ESLT), the largest publicly owned defense contractor in Israel, with subsidiaries operating in multiple countries under different governmental and private contracts, among them contracts with US government. Mr. Raviv led over 15 audit teams engaged in the global audit of Elbit Systems Ltd and its subsidiaries. In his last position, as Corporate Controller of DarioHealth Corp. (Nasdaq: DRIO), Mr. Raviv facilitated the company’s up-listing process to the Nasdaq in March 2016.Mr. Raviv joined as our Director of Finance in January of 2017 to oversee the company’s global finance organization. His deep understanding of multi-national global organizations and extensive experience with executive teams, provide him with the leadership and insight that make him an integral part of our team.